These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32817069)

  • 1. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors.
    Anand K; Sahu G; Burns E; Ensor A; Ensor J; Pingali SR; Subbiah V; Iyer SP
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
    Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN
    Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
    Ebinama U; Sheshadri A; Anand K; Swaminathan I
    J Immunother Precis Oncol; 2023 Nov; 6(4):177-184. PubMed ID: 38143955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Burns EA; Muhsen IN; Anand K; Xu J; Umoru G; Arain AN; Abdelrahim M
    J Immunother; 2021 Apr; 44(3):132-139. PubMed ID: 33480637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
    Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system.
    Shi H; He Y; Dan S; Yang L; Wang J; Chen L; Chen Z
    Front Med (Lausanne); 2024; 11():1366691. PubMed ID: 38711784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
    Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
    Liu Y; Chen Y; Zeng Z; Liu A
    Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
    Miyashita H; Mikami T; Satoi S; Cruz C; Galsky MD
    J Immunother; 2020; 43(9):291-298. PubMed ID: 32960847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
    Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
    Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors.
    Chen J; Wen Y; Chu X; Liu Y; Su C
    Front Pharmacol; 2022; 13():944342. PubMed ID: 36110543
    [No Abstract]   [Full Text] [Related]  

  • 17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
    Tafuri A; Smith DD; Cacciamani GE; Cole S; Shakir A; Sadeghi S; Vogelzang NJ; Quinn D; Gill PS; Gill IS
    Clin Genitourin Cancer; 2020 Oct; 18(5):351-360.e3. PubMed ID: 32146152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular adverse events in PD-1 and PD-L1 inhibitors.
    Young L; Finnigan S; Streicher H; Chen HX; Murray J; Sen HN; Sharon E
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34226280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and influencing factors of anti-PD-1/PD-L1-related severe cardiac adverse event: based on FAERS and TCGA databases.
    Cheng X; Lin J; Wang B; Huang S; Liu M; Yang J
    Sci Rep; 2024 Sep; 14(1):22199. PubMed ID: 39333574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.